PRecision Oncology CUhk pRogrammE (PRO-CURE)

NCT ID: NCT04724070

Last Updated: 2024-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-10-16

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main aim of this project is to establish an innovative model of a comprehensive precision oncology platform to help individualizing drug therapy for patients with advanced cancers at The Chinese University of Hong Kong. The other objectives include to optimize the genomic matching and access of patients with unique cancer subtypes to the relevant clinical trials of novel therapies, and to construct a personalized drug screening platform for individuals using novel cancer models established from patient-derived cancer cells and tissues. Other objectives include to investigate the utility and feasibility of genomic sequencing using circulating tumor DNA(ctDNA), and to establish a biobank of tumor tissues derived from patients with unique cancer subtypes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastrointestinal Cancers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

NGS and PDO/PDX establishment

NGS, PDO/PDX establishment

Intervention Type GENETIC

Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NGS, PDO/PDX establishment

Patients' tumor specimens will be collected for next generation sequencing, PDO/PDX establishment and tissue banking.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must be aged between 18 to 75 years
* Must have ECOG performance status of 0 to 1
* Must have histologically/cytologically confirmed cancers of certain subtype
* Medically fit patients who would need systemic therapy as part of their oncological treatment in any one or more of the following oncological setting(s): palliative, neoadjuvant, adjuvant, concurrent with radiotherapy. This includes patients who have limited systemic therapeutic options for their cancers and are candidates for clinical trials.
* Able to give written informed consent
* Willing to have blood samples taken.
* Availability of an archived paraffin-embedded tumor block

Exclusion Criteria

* Patients who refuse or are medically unfit for systemic therapy for their cancer
* Patients with more than one invasive cancers diagnosed over the last FIVE years.
* Patients without measurable tumor lesions on radiological imaging
* Patients who are unable to give written informed consent.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Brigette Ma

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Brigette Ma

Professor, Department of Clinical Oncology

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Chinese University of Hong Kong

Hong Kong, , Hong Kong

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Brigette MA, MD

Role: CONTACT

Alice KONG, PC

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Brigette MA, MD

Role: primary

Alice KONG, PC

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

PROCURE

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Prognostic Biomarker for CRC
NCT03928652 UNKNOWN